nifekalant

06/01/2007 - "[Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function]."
01/01/2007 - "Nifekalant (NF) is a novel class III antiarrhythmic agent that is effective in preventing life-threatening ventricular tachycardia/fibrillation (VT/VF). "
08/01/2003 - "Nifekalant hydrochloride (MS-551), a pure K(+) channel blocker, might be effective for postoperative recurrent ventricular tachyarrhythmias that are refractory to other antiarrhythmic agents."
10/01/2022 - "The patient was treated with nifekalant for 31 days, which effectively terminated ventricular tachycardia and maintained sinus rhythm, with no clinical adverse reactions. "
01/01/2019 - "In patients with paroxysmal supraventricular tachycardia, nifekalant significantly prolonged the effective refractory period, the block cycle length of the antegrade accessory pathway, and the atrial effective refractory period (all P<0.001). "

01/01/2005 - "Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation."
02/01/1995 - "The data indicate that a multiple-dose regimen of MS-551 provides protection against ischemia-induced ventricular fibrillation (VF) in the postinfarcted heart. "
08/11/2023 - "Nifekalant is used to prevent ventricular tachycardia/ventricular fibrillation. "
05/20/2021 - "We report a case of successful management in preventing ventricular fibrillation under hypothermia by using nifekalant. "
04/01/2006 - "Although nifekalant is a class III antiarrhythmic agent without negative inotropic activity, its effect in patients with shock-refractory ventricular fibrillation remains unclear. "

11/01/2010 - "Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm."
01/01/2006 - "Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? "
09/01/2006 - "Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: experimental study in a canine model of cardiopulmonary arrest."
09/01/2006 - "Because nifekalant hydrochloride (NIF) displayed a superior defibrillating effect on ventricular tachycardia/fibrillation (VT/VF) in cardiopulmonary arrest (CPA) patients, despite some QT prolongation, its effect on transmural dispersion of repolarization (TDR) in the left ventricle (LV) in an animal model of CPA was investigated. "
08/01/2010 - "To compare the efficacy of nifekalant and amiodarone in the treatment of cardiac arrest in a porcine model. "

10/01/2022 - "On the basis of nifekalant's working mechanism, there is a good chance that it can cure ventricular arrhythmia on a long-term basis."
03/01/2021 - "Nifekalant has been used in the treatment of atrial arrhythmia recently. "
02/26/2019 - "Higher doses of nifekalant induced ventricular arrhythmia in 3 out of 4 animals, in which both the short-term and long-term variability of the QT interval increased just before the occurrence of arrhythmia. "
02/26/2019 - "Electrophysiological analysis showed nifekalant at 0.3 mg/kg prolonged QT/QTc intervals with no evidence of arrhythmia. "
07/01/2005 - "Nifekalant improves the prognosis for life-threatening ventricular arrhythmia in IHD patients."

11/28/2020 - "Intraprocedural Conversion Efficacy of Intravenous Nifekalant Administration for Persistent Atrial Fibrillation after Pulmonary Vein Isolation."
01/01/2019 - "Background The efficacy of nifekalant in preexcited atrial fibrillation ( AF ) has not been assessed. "
01/01/2023 - "Meta‑analysis of the efficacy and safety of nifekalant in the conversion of atrial fibrillation."
03/01/2021 - "However, there is no consensus on the preferable nifekalant dose to treat atrial fibrillation (AF). "
06/01/2020 - "Atrial fibrillation was successfully managed with temporary atrial pacing and administration of nifekalant hydrochloride without invasive mechanical circulatory support until surgery. "